FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892935799> ?p ?o ?g. }

• W2892935799 endingPage "41" @default.
• W2892935799 startingPage "39" @default.
• W2892935799 abstract "It is remarkable that even though 30 years have passed since the introduction of prostate-specific antigen (PSA)2 into US clinical practice, researchers and clinicians are still debating its value for prostate cancer screening. The US Preventive Services Task Force has seesawed from stating that PSA testing was a personal decision for the individual man in 2008, to concluding “moderate or high certainty that … the harms outweigh the benefits” in 2012, to recommending shared decision-making once again in 2018 (1). In most industrialized countries, government-sanctioned guideline groups recommend against population-based screening, yet PSA testing remains common in everyday practice throughout the Western world.My own view is that the PSA debate has lost the forest for the trees. White papers and recommendation statements focus on subtle points of scientific methodology—such as whether postrandomization consent results in the loss of allocation concealment—while giving sparse attention to some larger facts and principles. Here, I lay out 3 simple, established, and accepted propositions about PSA screening and argue that these lead to some straightforward conclusions.For many years, it was open to reasonable debate as to whether PSA screening did, in fact, reduce prostate cancer mortality. Recent data have ended this debate. There has been only 1 methodologically acceptable randomized trial of PSA screening, the European Randomised Study of Screening for Prostate Cancer (ERSPC), and this trial clearly showed a reduction in prostate cancer mortality (2). Similarly, recent US population trends showing reductions of 40% to 50% in prostate cancer mortality since the pre-PSA era cannot be explained without reference to a screening effect (3).The harms of PSA screening, on the other hand, are well known. Prostate cancer generally has a very indolent course, such that a large proportion of screen-detected cancers would never have been diagnosed during the patient's …" @default.
• W2892935799 created "2018-10-05" @default.
• W2892935799 creator A5025886998 @default.
• W2892935799 date "2019-01-01" @default.
• W2892935799 modified "2023-10-16" @default.
• W2892935799 title "Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis" @default.
• W2892935799 cites W1594257104 @default.
• W2892935799 cites W1980762548 @default.
• W2892935799 cites W2035446368 @default.
• W2892935799 cites W2037994620 @default.
• W2892935799 cites W2055228524 @default.
• W2892935799 cites W2082255769 @default.
• W2892935799 cites W2098929750 @default.
• W2892935799 cites W2103212323 @default.
• W2892935799 cites W2120357482 @default.
• W2892935799 cites W2160217483 @default.
• W2892935799 cites W2735211627 @default.
• W2892935799 cites W2765984831 @default.
• W2892935799 cites W2966258052 @default.
• W2892935799 doi "https://doi.org/10.1373/clinchem.2018.287094" @default.
• W2892935799 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6709846" @default.
• W2892935799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30274977" @default.
• W2892935799 hasPublicationYear "2019" @default.
• W2892935799 type Work @default.
• W2892935799 sameAs 2892935799 @default.
• W2892935799 citedByCount "14" @default.
• W2892935799 countsByYear W28929357992020 @default.
• W2892935799 countsByYear W28929357992021 @default.
• W2892935799 countsByYear W28929357992022 @default.
• W2892935799 countsByYear W28929357992023 @default.
• W2892935799 crossrefType "journal-article" @default.
• W2892935799 hasAuthorship W2892935799A5025886998 @default.
• W2892935799 hasBestOaLocation W28929357991 @default.
• W2892935799 hasConcept C121608353 @default.
• W2892935799 hasConcept C126322002 @default.
• W2892935799 hasConcept C143998085 @default.
• W2892935799 hasConcept C2775941076 @default.
• W2892935799 hasConcept C2776235491 @default.
• W2892935799 hasConcept C2779377019 @default.
• W2892935799 hasConcept C2780192828 @default.
• W2892935799 hasConcept C2781406297 @default.
• W2892935799 hasConcept C29456083 @default.
• W2892935799 hasConcept C71924100 @default.
• W2892935799 hasConceptScore W2892935799C121608353 @default.
• W2892935799 hasConceptScore W2892935799C126322002 @default.
• W2892935799 hasConceptScore W2892935799C143998085 @default.
• W2892935799 hasConceptScore W2892935799C2775941076 @default.
• W2892935799 hasConceptScore W2892935799C2776235491 @default.
• W2892935799 hasConceptScore W2892935799C2779377019 @default.
• W2892935799 hasConceptScore W2892935799C2780192828 @default.
• W2892935799 hasConceptScore W2892935799C2781406297 @default.
• W2892935799 hasConceptScore W2892935799C29456083 @default.
• W2892935799 hasConceptScore W2892935799C71924100 @default.
• W2892935799 hasFunder F4320306163 @default.
• W2892935799 hasFunder F4320337351 @default.
• W2892935799 hasIssue "1" @default.
• W2892935799 hasLocation W28929357991 @default.
• W2892935799 hasLocation W28929357992 @default.
• W2892935799 hasLocation W28929357993 @default.
• W2892935799 hasLocation W28929357994 @default.
• W2892935799 hasOpenAccess W2892935799 @default.
• W2892935799 hasPrimaryLocation W28929357991 @default.
• W2892935799 hasRelatedWork W1980245127 @default.
• W2892935799 hasRelatedWork W1987689285 @default.
• W2892935799 hasRelatedWork W1996423854 @default.
• W2892935799 hasRelatedWork W2109046819 @default.
• W2892935799 hasRelatedWork W2168939427 @default.
• W2892935799 hasRelatedWork W2171626530 @default.
• W2892935799 hasRelatedWork W2526330449 @default.
• W2892935799 hasRelatedWork W2966258052 @default.
• W2892935799 hasRelatedWork W3006876728 @default.
• W2892935799 hasRelatedWork W4286449076 @default.
• W2892935799 hasVolume "65" @default.
• W2892935799 isParatext "false" @default.
• W2892935799 isRetracted "false" @default.
• W2892935799 magId "2892935799" @default.
• W2892935799 workType "article" @default.